ABOS — Acumen Pharmaceuticals Share News
0.000.00%
Last trade - 00:00Brief: Acumen Pharmaceuticals To Report Fourth Quarter And Year-End 2024 Financial Results On March 27, 2025
Acumen Pharmaceuticals Inc reports results for the quarter ended September 30 - Earnings Summary
Brief: Acumen Pharmaceuticals, Inc. Q3 Income From Operations USD -32.265 Million
Acumen Pharmaceuticals Inc expected to post a loss of 36 cents a share - Earnings Preview
Brief: Acumen Pharmaceuticals Appoints Amy Schacterle As Chief Regulatory Officer & Head Of Quality
Brief: Acumen Pharmaceuticals To Deliver Late-Breaking Presentation At 17Th Annual Clinical Trials On Alzheimer’S Disease (Ctad) Conference
Brief: Acumen Pharmaceuticals Extends Collaboration With Lonza To Add Drug Product Manufacturing Of Sabirnetug For Early Alzheimer’S Disease
Acumen Pharmaceuticals Inc reports results for the quarter ended in June - Earnings Summary
Acumen Pharmaceuticals Inc expected to post a loss of 28 cents a share - Earnings Preview
Acumen Pharmaceuticals Inc expected to post a loss of 28 cents a share - Earnings Preview
Acumen Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary
Acumen Pharmaceuticals Inc expected to post a loss of 26 cents a share - Earnings Preview
Acumen Pharmaceuticals Inc expected to post a loss of 26 cents a share - Earnings Preview
Brief: Acumen Pharmaceuticals Inc Files For Mixed Shelf Of Up To $200 Million - SEC Filing
U.S. RESEARCH ROUNDUP-Acuity Brands, CSG Systems International, Nuvation Bio
Acumen Pharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary
Brief: Acumen Pharmaceuticals, Inc. FY Income From Operations USD -61.138 Million Vs. IBES Estimate USD -58.8 Million
Acumen Pharmaceuticals Inc expected to post a loss of 26 cents a share - Earnings Preview
Brief: Acumen Pharmaceuticals Says Co On Track To Initiate Phase 2 Trial Evaluating Sabirnetug In First Half Of 2024